Kornimate/medical-research-clean huggingface dataset:
ultrasound-guided injection of glucocorticoid into infrapatellar fat pad in patients with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: this aims of this study is to investigate the efficacy and safety of the glucocorticoid injection into the infrapatellar fat pad among knee osteoarthritis patients with an inflammatory phenotype.


Eligibility criteria:
inclusion criteria: 1. diagnosed with symptomatic knee osteoarthritis (oa) according to american college of rheumatology criteria; 2. age \> 45 years; 3. have knee pain for more than six months and the knee pain over the past week assessed by vas (100 mm) ≥ 40 mm; 4. ultrasonography showed obvious synovitis with effusion in the knee joint; 5. both mri-assessed hoffa-synovitis score (moaks method) and effusion-synovitis score (modified worms method) ≥ 1, and their total score ≥ 3; 6. being able to listen, speak, read and understand chinese, capable of understanding the study requirements and cooperating with the researchers during the study, and providing written informed consent. exclusion criteria: 1. allergy to glucocorticoids; 2. knee injection of glucocorticoid or hyaluronic acid within the past six months; 3. severe trauma or arthroscopy in the knee within the past six months; 4. planned hip or knee surgery (including arthroscopy, arthroplasty, and other open joint surgeries) in the next six months; 5. contraindication to having magnetic resonance imaging (mri) (e.g., implanted pacemaker, artificial metal valve or cornea, aneurysm clipping surgery, arterial dissection, metal foreign bodies in the eyeball, claustrophobia); 6. presence of other arthritis, such as rheumatoid arthritis and psoriatic arthritis; 7. other physical condition that is more painful than their knee oa; 8. malignant tumors or other life-threatening diseases; 9. infection, diabetes, coagulopathy, osteonecrosis, or gastric/duodenal ulcer within the past 12 months; 10. current use of oral corticosteroids, nonsteroidal anti-inflammatory drugs, or immunosuppressive medication; 11. pregnancy or lactating female; 12. use any investigational drugs or devices in the recent 30 days.

Keywords: knee osteoarthritis infrapatellar fat pad inflammatory osteoarthritis glucocorticoid
diagnosis assessment with diaana #3

Conditions: Decision Making; Computer-assisted; General Practitioners; Patient Engagement

Summary: single-center, unblinded, 2:1 parallel pseudo-randomized efficacy trial. in the intervention group only, resident physicians will be assisted by the automated medical history-taking device "diaana" during their consultations in outpatient ambulatory unit of the geneva university hospital. in both groups, the differential diagnosis of the resident physician will be compared to the gold-standard diagnosis of the senior physician.

automated medical history-taking devices (amhtd) are emerging tools with the potential to increase the quality of medical consultations by providing physicians with an exhaustive, high-quality, standardized anamnesis and differential diagnosis. in this study, the investigators aimed to establish whether an amhtd of interest, "diaana", allowed the physician to establish a more precise differential diagnosis. a single-center, unblinded, 2:1 parallel pseudo-randomized efficacy trial will be performed. a consultation follow-up is organized at 4-6 weeks, were the gold-standard diagnosis is established by the senior physician. the study will take place in the emergency outpatient unit of la colline hospital (geneva, switzerland) and include patients suffering from symptoms covered by diaana. patients in the intervention group will fulfill dianna. then, the resident physician will read diaana summary, perform his consultation, and fulfill case report form, including his differential diagnosis. then, the senior physician will see the patient and establish the gold-standard diagnosis. in the control group, the residents will directly establish a differential diagnosis, without the help of diaana.

Eligibility criteria:
inclusion criteria: * patients presenting to the emergency outpatient unit of la colline hospital (geneva, switzerland) * patients suffering from symptoms localized to the superior or inferior member, the back, hand the chest wall. exclusion criteria: * strictly dermatologic concerns * toes trauma (because the diagnosis of those conditions is generally obvious) * medical condition considered as urgent * inability to complete de digilatized diaana form (sight problems, language, inability to use a tablet computer)

Keywords: differential diagnosis hospital outpatient clinics clinical applications software
study to investigate genetic causes of severe early childhood onset obesity.

Conditions: Obesity

Summary: this study aims to investigate genetic causes of early childhood obesity. the investigators will enroll children and adults with severe early onset obesity (bmi \> 99th percentile) diagnosed prior to 6 years of age. the investigators will ask questions about the health and eating behavior of the participants, and perform a brief physical examination. the investigators will collect saliva or blood to perform genetic testing from the participants and invite family members to enroll in the study.

this is a clinical and genomic study designed to investigate monogenic causes of severe early childhood obesity. participants with severe early onset obesity will be identified by screening of the clinical database or referred for the study. these subjects will be invited to participate in the study. after obtaining informed consent, the investigators will obtain history on the proband and the family, and perform a brief examination in addition to collecting genetic material. targeted sequencing of genes associated with monogenic and syndromic forms of obesity will be performed using next-generation sequencing. in selected individuals with favorable family history, exome or whole genome sequencing will be performed. functional analysis of newly identified variants will be performed where possible.

Eligibility criteria:
inclusion criteria: - bmi \> 99th percentile documented at age \< 6 years of age exclusion criteria: * known genetic causes of obesity * known endocrine causes of obesity. * neurologic tumor, trauma or surgery * prior malignancy or transplant * known autoimmune diseases * edema of a known or unknown cause * prolonged steroid use.

Keywords: obesity genetics early-onset childhood
testing a novel instagram intervention for heavy alcohol use

Conditions: Heavy Drinking

Summary: this project aims to test the efficacy of an instagram-based intervention for reducing heavy alcohol use. more specifically, the investigators will use a randomized controlled design to analyze differences in alcohol use and alcohol-related outcomes (e.g., alcohol-related consequences, etc.) as well as differences in the use of protective behavioral strategies and mindfulness practices. participants (80 prolific users who report binge drinking) will be randomly assigned to 1 of 3 conditions: intervention or control. those who are randomized to the intervention condition will be invited to follow study instagram pages, and those who are randomized to the control condition will be invited to complete the assessments only. the investigators hypothesize that there will be greater reductions in alcohol use, frequency, and consequences and greater frequency of use of mindfulness exercises and protective behavioral strategies among those in the intervention condition as compared to those in the control condition.


Eligibility criteria:
inclusion criteria: * ages 18-30 * report regular instagram usage (i.e., at least a few times a week) * report having met the niaaa's criteria for a binge-drinking episode (4+ drinks in a sitting for cisgender women, 5+ drinks in a sitting for all other genders) at least twice a month for the past three month exclusion criteria: * no exclusion criteria
secondary prevention treatment in patients who have suffered a cardiovascular event

Conditions: Cardiovascular Events

Summary: astrazeneca was interested in knowing how cardiologists and physicians treat patients who have suffered a cardiovascular event.


Eligibility criteria:
inclusion criteria: * all patients who has experienced cardiovascular events exclusion criteria: * patients with no cardiovascular events.
amino acid and acylcarnitine profiles in premature neonates

Conditions: Prematurity; Neonatal Screening; Parenteral Nutrition

Summary: primary hypotheses of the study include: * metabolic profiles are influenced by gestational age, chronological age, type and degree of nutritional support and illness * metabolic profiles differ between neonates who receive commercial formula and neonates who receive primarily human breast milk * neonates who develop parenteral associated cholestasis have metabolic markers that identify at risk patients (high serum urea nitrogen, citrulline, histidine, methionine, and succinyl carnitine and low thyroxine, serine and glutamate) * neonates that have hypothyroidism have abnormal metabolic profiles (low tyrosine levels)

malnutrition is a common problem in the neonatal intensive care unit. recent studies indicate that prematurely born neonates commonly develop a severe nutritional deficit during the first weeks after birth, referred to as extrauterine growth restriction. despite an increase in growth during the second month of hospitalization, many neonates are ultimately discharged home having grown inadequately. the early nutritional deficit affects weight gain as well as growth in length and head circumference. aggressive administration of parenteral amino acids to improve protein accretion rates in very preterm neonates has been supported in the literature. although tolerance of high dose amino acids has been described, researchers acknowledge that sensitive tests to monitor amino acid toxicity are not readily available in the clinical setting. the goals of this study are: * to better define normal amino acid and acylcarnitine values and how they change in premature neonates * to measure the effect nutritional support has (human breastmilk vs. formula) on amino acid and acylcarnitines profiles * to measure the effect of illness (parenteral nutrition associated cholestasis) on amino acid and acylcarnitine profiles * to better define abnormal metabolic profiles (low tyrosine levels) in neonates that have hypothyroidism.

Eligibility criteria:
inclusion criteria * documentation of informed consent * inborn * less than or equal to twenty four (24) hours of age * gestational age between twenty three (23) weeks and 0/7 days and thirty one (31) weeks and 0/7 days as per the best estimate by the neonatologist * if subject is transferred to another hospital, the ability to obtain follow-up data on outcomes * no known major anomalies (inborn error of metabolism, chromosomal abnormalities, cyanotic congenital heart disease, gastroschisis, omphalocele, diaphragmatic hernia or other major gastrointestinal anomalies, major neurological injury or anomaly, and multiple congenital anomalies) exclusion criteria * outborn (transferred for intensive care from another hospital) * greater than twenty four (24) hours of age * gestational age \ 31 weeks * any known major congenital anomalies

Keywords: prematurity neonatal screening parenteral nutrition amino acids acylcarnitine
pet imaging in parkinson disease dementia

Conditions: Parkinson's Disease

Summary: the purpose of this study is to use a brain imaging method called pib pet to determine dementia subtypes in patients with parkinson's disease. the ultimate goal of this project is to be able to identify individuals with pd who are at risk of developing dementia, and to distinguish the underlying cause of dementia.

the purpose of this study is to use a brain imaging method called pib pet to determine dementia subtypes in patients with parkinson's disease. the ultimate goal of this project is to be able to identify individuals with pd who are at risk of developing dementia, and to distinguish the underlying cause of dementia. we will be including both pd and normal subjects in this study. this a long term study and we are considering including a total of 320 participants in this protocol.

Eligibility criteria:
inclusion criteria: * pd patients must exhibit three of the following cardinal signs: rest tremor, rigidity, bradykinesia, or postural instability; or two of these features with one of the first three displaying asymmetry. exclusion criteria: * history of head trauma, major neurological or psychiatric diseases other than parkinson disease and dementia, e.g. stroke, multiple sclerosis, depression or schizophrenia * severe systemic diseases * inability to lie still for 90 minutes * metallic implants, pacemakers, or any other contraindication to mri * refusal to consent to brain donation

Keywords: parkinson disease pet imaging pib dementia
intensive outpatient versus outpatient treatment with buprenorphine among african americans

Conditions: Drug Dependence

Summary: the purpose of this study is to compare the effectiveness of different levels of counseling (intensive outpatient versus standard outpatient) on treatment outcomes for african american adult patients receiving buprenorphine in 2 formerly "drug-free" programs.

this two-group randomized clinical trial will test the effectiveness of intensive outpatient (iop) v. standard outpatient (op) treatment in 272 heroin-dependent african american adults receiving buprenorphine in 2 formerly "drug-free" programs. participants will be randomly assigned to one of the two treatment intensity conditions at intake and assessed at baseline, 3-, and 6-months post-baseline to determine treatment retention, frequency and severity of heroin and cocaine use, self-reported hiv-risk, quality of life, and to determine dsm-iv criteria for full or partial remission of opioid dependence. furthermore, patient factors potentially critical for treatment success (e.g., attitudes towards buprenorphine and average buprenorphine dose while in treatment) will be examined to determine their importance in influencing treatment outcomes. moreover, both patient and staff attitudes and average buprenorphine dose will be evaluated to determine their respective relationships to treatment experiences and treatment retention.

Eligibility criteria:
inclusion criteria: * heroin-dependent adults * new admissions to buprenorphine outpatient treatment exclusion criteria: * pregnancy * acute medical or psychiatric illness

Keywords: opioid dependence outpatient treatment intensive outpatient treatment
senoc-i det sunda huset ii - sensitization of occupants of water damaged buildings.

Conditions: Upper Airway, Irritation Inflammation, Discomfort

Summary: the study is focussed on two main questions: 1. the importance of dampness of the building and home dust as a factor of the subjects= responses. 2. can measures used in klinir predict the subjects' responses to the dust? this study therefore was arranged to test the following hypotheses: 1. does dust in general cause inflammatory/body perceptions through e.g. an irritation symptoms index. 2. does the dust include effective odorants which affects an iaq index? 3. does dampness increase the content of organic or inorganic compounds e.g. of microbial origin that causes the dust to be more reactive? (differences between the two types of dust) 4. is the sensitivity of the subjects explaining the responses to exposures in a, b, or c? (subject group and sensitivity index) as explorative investigations biomarkers for exposures and sensitivity for practical usage are tested.

the study is focussed on two main questions: c. the importance of dampness of the building and home dust as a factor of the subjects= responses. d. can measures used in klinir predict the subjects' responses to the dust? as explorative investigations biomarkers for exposures and sensitivity are tested for practical use. these investigations are made during experimental exposures of subjects to dust from dry and water damaged buildings. the responses of healthy klinir-sensitive subjects are predicted using personal sensitivity measures. the design is a 3x3 latin square design (cross-over design). the subjects will be their own controls and comparisons to placebo (clean air) were made. the study was double blinded and the subjects were only informed about details on design and exposures after the experiment and only if they asked. this design eliminated effects of any learning or training during the investigations, and also the effects of season and weekday was eliminated. the subjects were exposed with 3-4 weeks interval to eliminate carry-over of effects from one exposure session to the next. the design was replicated three times on three different groups of subjects each including 9 subjects. each group of nine were divided into three groups of three subjects.

Eligibility criteria:
inclusion criteria: * all in local area, nasal histamine responsive, grass allergic, from study klinir. exclusion criteria: * pregnancy, house dust allergy, hyper-responding air ways, disease, disabled

Keywords: upper airway, irritation inflammation, discomfort, house dust, damp buildings, climate chamber, humans
national acalabrutinib observational study

Conditions: Chronic Lymphocytic Leukemia

Summary: the efficacy and safety of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (cll) have been well established through 3 phase iii clinical trials (elevate tn, ascend, elevate r/r) that led to european medicines agency approval in november 2020. the aim of this french longitudinal, non-interventional/observational, multicenter study is to describe the efficacy and safety of acalabrutinib treatment for cll patients in real life. the primary objective is then to estimate the time to discontinuation of acalabrutinib therapy and the reasons for discontinuation, overall and by treatment line. the secondary objectives are to describe the baseline clinical and demographic characteristics of patients with cll treated with acalabrutinib, to assess the efficacy of acalabrutinib through progression-free survival, overall survival, time to next treatment or death, describe acalabrutinib treatment patterns in cll patients and reasons, identify key determinants of acalabrutinib discontinuation in cll patients, estimate healthcare resource utilization. the overall response rate will be estimated as an exploratory objective. patients included in this study will be cll patients treated with acalabrutinib at the discretion of their physician between january 1, 2021 and december 31, 2022, who have been informed of the study and do not object to electronic processing of their data for research purposes (or do not object during their lifetime in the event of the patient's death prior to study initiation). secondary data will be extracted from the hospital's patient records once a year. the protocol calls for the recruitment of 350 patients at 70 centres with a 3-year follow-up. interim analyses will be performed annually until the end of the study.


Eligibility criteria:
inclusion criteria: * male or female patients aged ≥ 18 years old, * cll patients initiated with acalabrutinib at their physician's discretion between january 1st 2021 and december 31st 2022, * patients alive at study initiation and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician); or patient who died before study initiation and who did not object to data collection for research purpose(s) during his or her lifetime. exclusion criteria: * patients participating in a clinical trial with an investigational drug within 30 days prior to acalabrutinib initiation, * patients who initiated acalabrutinib treatment before january 1st 2021.
nutrition and neurological development of very preterm infants

Conditions: Premature Infant; Infant Nutrition Disorders; Delayed Mental Development

Summary: the main goal of this study is to determine, in preterm infants born with a ga \< 32 weeks, the association between: * the quantity of mother's milk and duration and breastfeeding * the intake of polyunsaturated fatty acids and iron during hospitalizations

the main hypothesis of this study is that the intake of lipid during hospitalization in neonatology department is associated with neurological development of preterm infants born with a ga \< 32 weeks. the other hypotheses are that iron intake and the duration of breastfeeding are also associated with the development of preterm infants. in the previous study epinutri (nct01486173), the development of infants was evaluated until the age of 1 year. epinutri_3 is the follow-up of epinutri until the age of 3 years. the aim of epinutri_3 study is to determine the association between lipid intake during hospitalization in neonatology department of preterm infants born with a ga \< 32 weeks. the secondary objective is : - to evaluate the association between these factors and communication, developmental and social-emotional delays with the test " ages and stages questionnaire " (asq) at 3 years of age.

Eligibility criteria:
inclusion criteria: * premature infants previously included in epinutri study * non opposition of the parents for the collection of clinical and nutritional data exclusion criteria: * refusal of the parents to collect clinical and nutritional data

Keywords: premature infants nutritional status polyunsaturated fatty acids status
smartwatch and physician well-being

Conditions: Professional Burnout

Summary: the prevalence of burnout and other forms of distress among physicians is alarmingly high. this clinical trial is being conducted to learn more about if wearing a smartwatch and having access to its data improves physicians' sense of well-being and if data measured from smartwatches contain a 'signal' that predicts well-being

we will conduct a randomized controlled trail to evaluate if wearing a smartwatch improves overall well-being among physicians, and if so, in which dimension of well-being (e.g., fatigue, stress, overall quality of life, burnout). additionally, we will explore if data from smartwatches can predict subsequent well-being among physicians. study aims: 1. to determine if wearing a smartwatch and having access to its physiological data (e.g., sleep, step count, activity, breathing reminders) improves well-being, and if so which well-being dimensions. 2. to determine whether continuous physiological measures (measured from smartwatches) contain a 'signal' that predicts physician well-being, and if so in which dimensions.

Eligibility criteria:
inclusion criteria: * physician exclusion criteria: * non physicians